Evidence map›Paper›PMID 25245933›Full record

ArticleVaccine2014

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Samir K Lakhashe, Siddappa N Byrareddy, Mingkui Zhou, Barbara C Bachler, Girish Hemashettar, Shiu-Lok Hu, Francois Villinger, James G Else, Shannon Stock, Sandra J Lee and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Vaccination againstInfection and immunity · 2019
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 2 countries.

Samir K LakhasheTexas Biomedical Research Institute, San Antonio, TX, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Siddappa N ByrareddyDana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Mingkui ZhouTexas Biomedical Research Institute, San Antonio, TX, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Barbara C BachlerDana-Farber Cancer Institute, Boston, MA, USA.
Girish HemashettarDana-Farber Cancer Institute, Boston, MA, USA.
Shiu-Lok HuUniversity of Washington, Seattle, WA, USA.
Francois VillingerDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
James G ElseDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Shannon StockDana-Farber Cancer Institute, Boston, MA, USA.
Sandra J LeeDana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Diego A Vargas-InchausteguiVaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Egidio Brocca CofanoVaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Marjorie Robert-GuroffVaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Welkin E JohnsonBiology Department, Boston College, MA, USA.
Victoria R PolonisThe Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Donald N ForthalDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
Erwann P LoretETRAV Laboratory, Faculty of Pharmacy, Aix Marseille University/CNRS, 27 BD Jean Moulin, 13385 Marseille Cedex 5, France.
Robert A RasmussenDana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Ruth M RuprechtTexas Biomedical Research Institute, San Antonio, TX, USA; Southwest National Primate Research Center, San Antonio, TX, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rruprecht@txbiomed.org.
Dana-Farber Cancer Institute · USHarvard University · USNational Cancer Institute · USEmory University · USBoston College · USCentre National de la Recherche Scientifique · FRTexas Biomedical Research Institute · USUniversity of California, Irvine · USUniversity of Washington · USWalter Reed Army Institute of Research · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
WNV REPLIVAX VACCINE IN NON-HUMAN PRIMATESP51RR013986 · NCRR · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI GOLDBERG, ERWIN · 1999 to 2011
$79.1M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Development of a Vaccine for HIVAIDS: Humoral ImmunityZIABC011058 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$23.3M
Humoral Correlates of Protection Against HIVR01AI100703 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI RUPRECHT, RUTH MARGRIT · 2012 to 2016
$4.0M
Intrinsic Immunity and AIDSR01AI095092 · NIAID · HARVARD MEDICAL SCHOOL · PI JOHNSON, WELKIN E · 2011 to 2015
$3.0M
Intramural NIH HHSNCRR NIH HHS P51 RR013986NIAID NIH HHS P01 AI048240NIAID NIH HHS R01 AI095092NIAID NIH HHS R01 AI100703NIH HHS P51 OD011132NIH HHS P51 OD011133NIH HHS P51OD011133
6 · The paper itself

Abstract

We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. This SHIV strain exhibits many properties of transmitted HIV-1, such as tier 2 phenotype (relatively difficult to neutralize), exclusive CCR5 tropism, and gradual disease progression in infected RMs. Since no human AIDS vaccine recipient is likely to encounter an HIV-1 strain that exactly matches the immunogens, we immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low-level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses.

Indexed as

Immunity, MucosalAIDS VaccinesAnimalsAntibodies, NeutralizingGene Products, gagGene Products, nefHIV-1HIV AntibodiesHIV Envelope Protein gp160Immunity, CellularImmunity, HumoralMacaca mulattaRecombinant ProteinsSimian Immunodeficiency Virustat Gene Products, Human Immunodeficiency VirusVaccinationAIDS VaccinesAntibodies, NeutralizingGene Products, gagGene Products, nefHIV AntibodiesHIV Envelope Protein gp160Recombinant Proteinstat Gene Products, Human Immunodeficiency VirusVaccines, SyntheticADCCCellular immunityHeterologous tier 2 virusHIV vaccineRhesus monkeySHIV-C

Identifiers

PMID25245933
PMCPMC4343195
OpenAlexW2003491059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.